triazolam has been researched along with Cholestasis, Intrahepatic in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Cholestasis, Intrahepatic: Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cobden, I | 1 |
| Record, CO | 1 |
| White, RW | 1 |
1 other study available for triazolam and Cholestasis, Intrahepatic
| Article | Year |
|---|---|
Fatal intrahepatic cholestasis associated with triazolam.
Topics: Adult; Anti-Anxiety Agents; Cholestasis, Intrahepatic; Humans; Male; Triazolam | 1981 |